One-stop Diagnosis and Treatment for Suspected Lung Cancer: Combined RBS, nClE, OBCT and Ablation

Exclusion Criteria

• •Diffuse bilateral lung lesions unresponsive to ablation.
• •Contraindication to bronchoscopy or inability to tolerate/cooperate with bronchoscopy.
• •Severe bleeding tendency or irreversible coagulopathy (PT \>18 s, PTA \<40%).Platelet count \<70×10⁹/L; anticoagulant/antiplatelet therapy discontinued \<1 week before ablation (except prophylactic low-molecular-weight heparin).
• •Severe pulmonary impairment (maximal voluntary ventilation \<40%).
• •Other metastatic tumors with widespread metastasis; life expectancy \<3 months.
• •Poor general condition: widespread metastasis, severe infection, high fever, infectious/radiation inflammation around the lesion, obvious cachexia, severe organ dysfunction, severe anemia, uncorrectable metabolic/nutritional disorders.
• •Eastern Cooperative Oncology Group (ECOG) performance status \>2.
• •Target lesion received radiotherapy within the past 6 months.
• •Active hepatitis B, active hepatitis C, known HIV-1/2 antibody positivity, or other active infections judged by the investigator to interfere with treatment.
• •History of epilepsy, psychosis, or cognitive impairment.
• •Pregnant/lactating females; males or females planning conception during the trial.
• •Other conditions deemed inappropriate by the investigator.